EBL vs APC for GAVE.pdf
4.1 MB
Endoscopic band ligation versus argon plasma coagulation in the treatment of gastric antral vascular ectasia: systematic review and meta-analysis.
GIE june 2025
❤1
AGA guidelines Crohn’s disease 2025.pdf
7 MB
AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease.
AGA 20 November 2025
❤1
PIIS0016508525061608 conv 0.png
1.9 MB
Spotlight: Pharmacologic Management of Moderate-to-Severe Crohn’s Disease
❤1
Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial
👍1
PIIS0016508525059645.pdf
2.9 MB
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis.
For Summary press comment 👇
For Summary press comment 👇
AGA November 2025
Safety_of_uninterrupted_anticoagulation_in_the_setting_of_routine.pdf
598 KB
Safety of uninterrupted anticoagulation in the setting of routine colonoscopy
Summary 👇
GIE December 2025
Summary 👇
GIE December 2025
The most appropriate initial treatment for a patient whose stomach biopsy findings show Helicobacter pylori infection and dense infiltrates of B-cells of the mucosal lymphoid tissue (representing MALT lymphoma) includes antibiotics for the Helicobacter pylori infection. This treatment results in a remission in 50% to 80% of patients with H. pylori-associated gastric mucosal-associated lymphoid tissue lymphoma.
❤6
A marked increase in polyps from the previous colonoscopy in a patient with FAP is an indication for proctocolectomy with ileoanal anastomosis. Other indications for proctocolectomy with ileoanal anastomosis are colorectal cancer, high-grade dysplasia, and inability to survey the colon because of polyps. This patient requires continuous follow-up after surgery because cancer can occur in the ileum or the remaining rectum.
❤2
HIV infection cycle within a host cell.
HIV first binds to CD4 and CCR5 receptors (1), followed by membrane fusion (2). Once inside, viral RNA is converted into DNA by reverse transcriptase (3), which integrates into the host genome (4). The proviral DNA is transcribed (5) and translated (6) into viral proteins. New viral components assemble near the cell membrane (7) and are released as mature infectious virions.
Each step is a therapeutic target, with antiretroviral drugs designed to block viral replication and prevent immune system destruction.
HIV first binds to CD4 and CCR5 receptors (1), followed by membrane fusion (2). Once inside, viral RNA is converted into DNA by reverse transcriptase (3), which integrates into the host genome (4). The proviral DNA is transcribed (5) and translated (6) into viral proteins. New viral components assemble near the cell membrane (7) and are released as mature infectious virions.
Each step is a therapeutic target, with antiretroviral drugs designed to block viral replication and prevent immune system destruction.